Anticonvulsants for cocaine dependence
Open accessThe DOI matches its OpenAlex record; 14 of the 14 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Cocaine dependence is a major public health problem that is characterised by recidivism and a host of medical and psychosocial complications. Although effective pharmacotherapy is available for alcohol and heroin dependence, none is currently available for cocaine dependence, despite two decades of clinical trials primarily involving antidepressant, anticonvulsivant and dopaminergic medications. Extensive consideration has been given to optimal pharmacological approaches to the treatment of individuals with cocaine dependence, and both dopamine antagonists and agonists have been considered. Anticonvulsants have been candidates for use in the treatment of addiction based on the hypothesis that seizure kindling-like mechanisms contribute to addiction. OBJECTIVES: To evaluate the efficacy and safety of anticonvulsants for individuals with cocaine dependence. SEARCH METHODS: We searched the Cochrane Drugs and Alcohol Group Trials Register (June 2014), the Cochrane Central Register of Controlled Trials (CENTRAL) (2014, Issue 6), MEDLINE (1966 to June 2014), EMBASE (1988 to June 2014), the Cumulative Index to Nursing and Allied Health Literature (CINAHL) (1982 to June 2014), Web of Science (1991 to June 2014) and the reference lists of eligible articles. SELECTION CRITERIA: All randomised controlled trials and controlled clinical trials that focus on the use of anticonvulsant medications to treat individuals with cocaine dependence. DATA COLLECTION AND ANALYSIS: We used the standard methodological procedures expected by The Cochrane Collaboration. MAIN RESULTS: We included a total of 20 studies with 2068 participants. We studied the anticonvulsant drugs carbamazepine, gabapentin, lamotrigine, phenytoin, tiagabine, topiramate and vigabatrin. All studies compared anticonvulsants versus placebo. Only one study had one arm by which the anticonvulsant was compared with the antidepressant desipramine. Upon comparison of anticonvulsant versus placebo, we found no significant differences for any of the efficacy and safety measures. Dropouts: risk ratio (RR) 0.95, 95% confidence interval (CI) 0.86 to 1.05, 17 studies, 20 arms, 1695 participants, moderate quality of evidence. Use of cocaine: RR 0.92, 95% CI 0.84 to 1.02, nine studies, 11 arms, 867 participants, moderate quality of evidence; side effects: RR 1.39, 95% CI 1.01 to 1.90, eight studies, 775 participants; craving: standardised mean difference (SMD) -0.25, 95% CI -0.59 to 0.09, seven studies, eight arms, 428 participants, low quality of evidence. AUTHORS' CONCLUSIONS: Although caution is needed when results from a limited number of small clinical trials are assessed, no current evidence supports the clinical use of anticonvulsant medications in the treatment of patients with cocaine dependence. Although the findings of new trials will improve the quality of study results, especially in relation to specific medications, anticonvulsants as a category cannot be considered first-, second- or third-line treatment for cocaine dependence.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
GRADE: an emerging consensus on rating quality of evidence and strength of recommendations
Guyatt, G. H., Oxman, A. D., Vist, G. E., Kunz, R., Falck-Ytter, Y., Alonso-Coello, P., & Schünemann, H. J. (2008) · BMJ · doi:10.1136/bmj.39489.470347.ad · Cited by 23,305
GRADE guidelines: 1. Introduction—GRADE evidence profiles and summary of findings tables
Guyatt, G., Oxman, A. D., Akl, E. A., Kunz, R., Vist, G., Brozek, J., Norris, S., Falck-Ytter, Y., Glasziou, P., & deBeer, H. (2011) · Journal of Clinical Epidemiology · doi:10.1016/j.jclinepi.2010.04.026 · Cited by 10,681
Di Chiara, G., & Imperato, A. (1988) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.85.14.5274 · Cited by 4,733
The addicted human brain: insights from imaging studies
Volkow, N. D., Fowler, J. S., & Wang, G.-J. (2003) · Journal of Clinical Investigation · doi:10.1172/jci18533 · Cited by 916
Amphetamine-induced dopamine release in human ventral striatum correlates with euphoria
Drevets, W. C., Gautier, C., Price, J. C., Kupfer, D. J., Kinahan, P. E., Grace, A. A., Price, J. L., & Mathis, C. A. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(00)01038-6 · Cited by 706
Schünemann, H. J., Jaeschke, R., Cook, D. J., Bria, W. F., El-Solh, A. A., Ernst, A., Fahy, B. F., Gould, M. K., Horan, K. L., Krishnan, J. A., et al. (2006) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200602-197st · Cited by 577
Antipsychotic medications for cocaine dependence
Indave, B. I., Minozzi, S., Pani, P. P., & Amato, L. (2016) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006306.pub3 · Cited by 122
Self-citationPET measures of amphetamine-induced dopamine release in ventral versus dorsal striatum
Drevets, W. (1999) · Neuropsychopharmacology · doi:10.1016/s0893-133x(99)00079-2 · Cited by 122
Kampman, K. M., Pettinati, H. M., Lynch, K. G., Spratt, K., Wierzbicki, M. R., & O’Brien, C. P. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.05.026 · Cited by 115
Kemp, D. E., Gao, K., Ganocy, S. J., Elhaj, O., Bilali, S. R., Conroy, C., Findling, R. L., & Calabrese, J. R. (2009) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.07m04022 · Cited by 103
Cited by
Luchenski, S., Maguire, N., Aldridge, R. W., Hayward, A., Story, A., Perri, P., Withers, J., Clint, S., Fitzpatrick, S., & Hewett, N. (2018) · The Lancet · doi:10.1016/s0140-6736(17)31959-1 · Cited by 430
Degenhardt, L., Mathers, B., Vickerman, P., Rhodes, T., Latkin, C., & Hickman, M. (2010) · The Lancet · doi:10.1016/s0140-6736(10)60742-8 · Cited by 423
Degenhardt, L., Glantz, M., Evans‐Lacko, S., Sadikova, E., Sampson, N., Thornicroft, G., Aguilar‐Gaxiola, S., Al‐Hamzawi, A., Alonso, J., Helena Andrade, L., et al. (2017) · World Psychiatry · doi:10.1002/wps.20457 · Cited by 267
Disulfiram for the treatment of cocaine dependence
Pani, P. P., Trogu, E., Vacca, R., Amato, L., Vecchi, S., & Davoli, M. (2010) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007024.pub2 · Cited by 255
Self-citationTreatment of stimulant use disorder: A systematic review of reviews
Ronsley, C., Nolan, S., Knight, R., Hayashi, K., Klimas, J., Walley, A., Wood, E., & Fairbairn, N. (2020) · PLOS ONE · doi:10.1371/journal.pone.0234809 · Cited by 222
“…primary or secondary outcome measures, including dropout (17 studies, RR: 0.95, 95% CI: 0.86, 1.05), cocaine use (9 studies, RR: 0.92, 95% CI: 0.84, 1.02), and side effects as measured by the number of participants reporting at least one side effect (8 studies, RR: 1.39, 95% CI: 1.01, 1.9) [33].”
Influential
Metadata
- Authors
- Minozzi, S., Cinquini, M., Amato, L., Davoli, M., Farrell, M., Pani, P. P., & Vecchi, S.
- Venue
- Cochrane Database of Systematic Reviews
- Publisher
- Elsevier BV
- Published
- 2015-04-17
- Issue
- 4
- Pages
- CD006754-CD006754
- ISSN
- 1361-6137 (ISSN-L)
- OpenAlex
- W2105025488
- Cited by
- 122
- References
- 14
- Type
- reference entry
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Anticonvulsants for cocaine dependence. https://app.cochat.ai/papers/10.1002/14651858.cd006754.pub4
- The paper
- Minozzi, S., Cinquini, M., Amato, L., Davoli, M., Farrell, M., Pani, P. P., & Vecchi, S. (2015). Anticonvulsants for cocaine dependence. Cochrane Database of Systematic Reviews. https://doi.org/10.1002/14651858.cd006754.pub4
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.